My SciELO
Services on Demand
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Revista Archivo Médico de Camagüey
On-line version ISSN 1025-0255
Abstract
SUGRANES MONTALVAN, Adianez et al. Use of the Valergen DP vaccine in allergic rhinitis. AMC [online]. 2011, vol.15, n.4, pp. 676-686. ISSN 1025-0255.
Background: allergic rhinitis produced a significant deterioration in the quality of life. Sublingual immunotherapy represents a natural way to induce tolerance in the allergic disorder. Objective: to assess the efficacy and safety of allergenic extract VALERGEN-DP from mite Dermatophagoides pteronyssinus as sublingual therapeutic vaccine in patients with allergic rhinitis. Method: a clinical trial, phase II, double-blind, parallel, randomized, controlled with a placebo group was conducted. Vaccines were provided via sublingual in an increasing dose schedule. The treatment had a minimal duration of one year with frequent evaluations. The 40 patients included, two groups of 20 were assigned, previous informed consent. Results: it was observed an average decrease in the mean of symptoms, as well as drugs consumption in the active group in relation to the placebo with 156,3 (p=0,000) and 43.5 (p = 0, 000) respectively. Values of the mean of skin reactivity declined in the active group not so in the placebo with 2.6 %. Only four adverse events were reported, none fatal, representing a 0.2 %. Conclusions: sublingual immunotherapy with Dermatophagoide pteronyssinus is safe and effective for the treatment of patients with allergic rhinitis.
Keywords : IMMUNOTHERAPY, ACTIVE; DERMATOPHAGOIDES PTERONYSSINUS; RHINITIS; CLINICAL TRIAL, PHASE II; ADMINISTRATION, SUBLINGUAL.